The Latest Cardiac and Vascular News
ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) […]
SHANGHAI, Sept. 23, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on the world’s largest and most influential American transcatheter cardiovascular therapy conference (TCT 2022). PADN is an innovative radiofrequency ablation technique in treating PH, […]
PALO ALTO, Calif., Sept. 22, 2022 /PRNewswire/ — DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following a cardiac surgery. The percutaneous electrical nerve stimulator (PENS) system can be used for up to three days for symptomatic relief of post-operative pain following […]
PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs. The Patients […]
Clinically relevant doses of C21 increase blood flow in humans Systemic blood pressure was unaffected, and no side effects were observed The forearm blood flow method is a robust technique for early clinical concept testing GOTHENBURG, Sweden, Sept. 22, 2022 /PRNewswire/ — Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing […]
Financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and Series A investors Longitude Capital, Medicxi and RxCapital CHARLOTTESVILLE, Va., Sept. 22, 2022 /PRNewswire/ — Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led […]
Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot removal in peripheral arterial and venous systems, including for diseases such as acute limb ischemia, vein thrombosis and pulmonary embolism First and only computer-aided mechanical […]
Grant Proceeds Will Support Pre-Clinical Studies LOS ALTOS, Calif., Sept. 22, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health. SBIR grants are intended to stimulate technological innovation and […]
Company to introduce the most advanced iteration of its signal processing technology at Cleveland Clinic’s Global EP Summit 2022, a world-class leadership symposium Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision […]
The findings were published in the American Heart Association’s Hypertension journal and showed consistency of program results across diverse populations. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, has released a new study evaluating the program’s results for various user population groups in order to demonstrate […]
